Resonandina

Company profile

Resonandina: A Pioneer in Sustainable Medical Leasing

Resonandina is a profitable, sustainable medical lease scale-up founded in the Netherlands, dedicated to making diagnostics accessible to everyone. By offering pay-per-use leasing of high-quality, capital-intensive diagnostic equipment (MRI, PET/CT, Linac and more), Resonandina bridges the gap for hospitals that lack the resources or expertise to acquire such solutions. This model not only provides access to advanced equipment but also ensures economic and social returns in all activities.

Problem: Hospitals often lack resources or knowledge for capital intensive medical equipment.

Solution: Resonandina developed an innovative all-inclusive pay-per-use medical lease model that makes diagnostics accessible for everyone.

Capital-intensive equipment becomes affordable for hospitals because a small amount has to be paid each month instead of a large lump sum. The key differentiator of Resonandina is the focus on a ‘simple’ and client oriented “B2B” business model based on “Pay-per-Use” lease with an “all-inclusive” package. The service includes project design, investment, installation, training, full maintenance, and extended life cycle (with upgrades, reuse, and recycling). The hospital has all the medical related responsibilities like patient logistics, quality management, liability and (insurance) invoicing.

Resonandina ensures that these hospitals can deploy advanced equipment so that diagnostics become affordable and available to all. This results in healthier people and fewer travel movements.

Resonandina started the services in 2015 in Bolivia with a step-by-step expansion to in the Americas. Submarkets are: “doctor owned” medium size hospitals, larger professionally managed hospitals, and Public Healthcare Services.

Having a unique concept of “use it, don’t own it” Resonandina is a market leader with focus on the “niche” of high-end medical diagnostic imaging. With a strong partnership with GE Healthcare and Varian. Fundamental is the Recurring Revenue model with long term (8+ years) contracts. With 18+ units producing, 10+ in installation, and a pipeline (2026+) for 25+ projects, there is a great potential.

Resonandina aims at 100+ projects with €27 million ARR by 2030. The market size is estimated at 100,000 projects by 2030. Resonandina successfully created a recognized market position, defined the service and operational execution, managed to create a rising ARR and profitability, has proven the concept, prepared footprints in the addressable markets and is ready for the leap ahead. In contrast to previous campaign communications, the current focus is primarily on the ‘home market’ with a more conservative projection of 100 instead of 500 projects in the Americas, with expansion to other continents planned at a later stage.

Use of funds

While previous rounds mainly financed MRI installations in Latin America, this new campaign marks an important step forward. For the first time, the crowd will help finance a linear accelerator (Linac) used in radiotherapy to treat cancer in combination with a PET/CT scanner able of early detection and staging of cancer.

A Linac accelerates electrons in a straight line to make high-energy X-rays and directs them precisely at tumors. This destroys cancer cells while minimizing damage to healthy tissue. Because the radiation can be shaped to the exact contours of the tumor, treatment is both effective and highly targeted.

Developments since the last funding round with Invesdor

You know this company already because of the last funding round? Find out more about what has happened since then.

Company Info 

Products and services

Resonandina developed an innovative sustainable medical lease model that makes diagnostics accessible for everyone.

High-Quality Equipment

Aligning with technological medical developments, hospitals need equipment that meets high standards—certified and guaranteed by manufacturers. Main areas of equipment include:

• General Medicine, Traumatology, Orthopedics, Neurosurgery, Oncology (MRI, CT).
• Cardiology, Neurology (Angio), Radiotherapy (Linear Accelerator, Brachytherapy).
• Nuclear Medicine (Cyclotron, PET/CT).
• Robotics (Operation Theatre).

Full-Service Maintenance

Resonandina provides comprehensive, long-term maintenance without hidden fees. This includes:

• Project design and site planning.
• Delivery and installation.
• Training, monitoring, and maintenance.
• Upgrades and parts replacement to extend the equipment’s lifespan.

All services are executed by the OEM or certified third parties, ensuring reliability and optimal performance.

Long-Term Commitment

Through partnerships, hospitals can focus on patient diagnostics while Resonandina manages the equipment’s technical functionality and output optimization. This results in reliable, efficient operations and improved healthcare delivery.

Upgrade & Reuse

At the end of a contract, equipment is upgraded to meet evolving expectations. Parts are reused or recycled, enhancing sustainability and extending the equipment’s life cycle. For example, Resonandina’s MRI program extends the life span of an MRI from 90,000 scans to 135,000 scans.

How does it work?

This model allows hospitals to offer advanced diagnostic services without the financial burden of purchasing equipment outright. By preserving operational liquidity and providing flexibility in financial planning, Resonandina ensures healthcare providers can focus on patient care. The pay-per-use system, combined with volume discounts, incentivizes hospitals to maximize equipment usage, improving both efficiency and profitability. Resonandina offers a practical, transparent, and affordable financial solution for hospitals.

By integrating flexible leasing solutions with comprehensive services, Resonandina ensures that hospitals can focus on patient care while improving operational efficiency and profitability.

Business model

Resonandina employs a unique business model that revolutionizes access to capital-intensive medical equipment by shifting the financial burden from upfront investment (CAPEX) to operational expenses (OPEX). This approach ensures that hospitals can acquire and operate state-of-the-art diagnostic equipment without compromising their financial stability.

Financial Model

Resonandina’s financial model is built on a pay-per-use system, where hospitals pay a fee for each diagnostic scan performed. This structure aligns costs directly with usage, making the service both scalable and affordable. Volume discounts incentivize hospitals to increase equipment utilization by lowering the cost per scan as usage grows. Additionally, hospitals commit to a minimum number of scans each month, guaranteeing a stable revenue stream for Resonandina while promoting optimal equipment use.

Hospitals generate income from each scan by billing patients or insurers based on local tariffs. For example, they might pay Resonandina $50 per scan for the first 350 scans and a reduced rate for higher volumes. This tiered pricing model supports hospital profitability while maintaining Resonandina’s recurring revenue. On average, Resonandina earns $300,000 to $350,000 annually in recurring revenue for every $1 million invested in medical equipment.

Contractual and Client Details

Resonandina enters into long-term lease agreements that typically last between 6 and 15 years, aligning with the economic life cycle of the equipment. The primary market includes medium-sized, doctor-owned hospitals and larger professionally managed facilities in underserved regions with over 250,000 inhabitants. These hospitals often face capital constraints, making Resonandina’s flexible leasing solutions an ideal fit. For larger institutions, the model provides financial flexibility, allowing them to invest in other critical areas while keeping their balance sheets free from heavy equipment assets.

Comprehensive Service Offering

Resonandina’s service package is designed to provide end-to-end support for hospitals, ensuring the smooth operation of leased equipment:

• Resonandina handles equipment acquisition and oversees delivery, installation, and site planning to ensure operational readiness.
• Full-service maintenance is included, covering parts replacement and technological upgrades to extend equipment lifespans.
• Training and support are provided to hospital staff to ensure efficient and effective use of the equipment.

Partnerships and Operational Support

Resonandina collaborates with leading original equipment manufacturers (OEMs) like GE Healthcare, Varian and certified local service providers. These partnerships guarantee high-quality installations, reliable maintenance, and optimal equipment performance throughout the contract duration.

Sustainability Focus

At the core of Resonandina’s model is a commitment to sustainability. Equipment is upgraded or recycled at the end of each contract, minimizing waste and reducing environmental impact. By extending the lifespan of diagnostic equipment, Resonandina supports responsible consumption and promotes sustainable practices in alignment with SDG 12.

Unique Selling Propositions (USPs)

Resonandina offers distinct advantages for both clients and investors:

• For Clients:
  • Affordable pay-per-use solutions under OPEX.
  • Comprehensive service packages, including financing, installation, training, and maintenance.
  • Proven expertise in local markets, supported by partnerships with top-tier OEMs.
• For Investors:
  • A solid 10-year track record in Latin America.
  • A history of debt-financed growth with strong returns.
  • A profitable scale-up led by an experienced team with operational, financial, and medical expertise.

Vision and Mission

• Vision: Support for healthier people through equitable access to diagnostic care and subsequent medical treatment for everyone.
• Mission: To make diagnostics accessible to everyone through innovative pay-per-use leasing models.

Market

Opportunity in the Americas in Radiotherapy

The radiotherapy market in the Americas offers substantial growth potential. Resonandina’s sustainable medical lease model addresses key challenges in this space.

Approximately 4.000 Linear Accelerators are installed in the US, theoretically complying with the international standard of 4 per million, but more than 50% is older than 10 years and the distribution is unequal in subpopulations. In Latam and Caribbean there are 800 installed, leaving space for 1.600+ to get to the international standards. And further also 50% +is older than 10 years.  So, the total opportunity in the Resonandina’s home market the Americas is estimated at 4.000. Giving it 10 years to change we are talking of 400 Linacs per year more than 1 per day. We estimate conservatively a potential market share of max 5% being 20 per year reaching 100 by 2030. NOTE this has for now not been included in the below presented financial projections.

Competitive Landscape

Unlike traditional sales and financing models offered by OEMs like Varian, Philips, and GE Healthcare, Resonandina provides a comprehensive pay-per-use solution with full-service support. This unique approach targets underserved markets, particularly in the Americas, where approximately 20% of hospitals cannot access capital-intensive equipment through conventional means. Resonandina stands out by addressing these needs with tailored leasing solutions for high-end medical imaging equipment.

Entry Barriers

Entering the diagnostic imaging and radiotherapy market poses significant challenges. High capital requirements make it difficult for new competitors to acquire and maintain advanced medical equipment. Building partnerships with OEMs and local service providers is essential to ensure reliable operations, further adding to the complexity of market entry.

Establishing trust and a strong reputation takes years of consistent service delivery through long-term contracts. Moreover, creating an international corporate structure and developing efficient sales channels demand substantial resources and expertise.

Resonandina has overcome these barriers through its well-established network, proven business model, and first-mover advantage. By securing partnerships, developing a robust operational framework, and consistently delivering value, Resonandina has positioned itself as a trusted leader in sustainable diagnostic solutions, ensuring long-term growth and impact.

Positioning and References

Resonandina is the market leader in its niche of high-end medical diagnostic imaging and radiotherapy, with conservatively more than 100 projects targeted and ARR revenue potential of €30+ million by 2030 aiming at doble or triple numbers in the period after. Current clients include CEDISA (Dominican Republic), Hospital Arco Iris (Bolivia), Kenko Saúde (Brazil), NeuroElectricoDiagnostico (Colombia), Clinica Borja (Ecuador), Clinica Previn(Peru), and the Ministry of Health (St. Vincent).

Management

Distribution of company shares

Resonandina is fully owned by QMED B.V., a private holding company controlled by founder and CEO Floriaan van Bemmelen and family. This 100% ownership structure means that strategic decisions are streamlined and fully aligned with the company’s mission and long-term vision. For investors, this brings important advantages:

• Clear leadership: With complete ownership, the CEO can act decisively without conflicting shareholder interests slowing down progress.

• Strong alignment of interests: As the sole shareholder, Floriaan’s personal commitment and financial interests are directly tied to Resonandina’s success, ensuring focus on sustainable value creation.

• Consistency in strategy: Investors benefit from a stable and coherent growth strategy, shaped by the founder’s deep expertise in healthcare and diagnostics.

This ownership structure provides a solid foundation for the company’s financing strategy and long-term growth.

Company structure

Developments at Resonandina since the last funding round

The company’s development over the past year shows a clear growth trajectory and performance is already exceeding earlier forecasts. Key milestones since the last funding round include:

• Strong financial performance: EBITDA increased from approx. $1.1 million in 2023 to $1.85 million in 2024. For 2025, an EBITDA of $3.8 million is expected – more than double this year’s result.

• Project delivery: In 2024, 7 projects were successfully installed. For 2025, 9 further projects are already planned (see pipeline in the financial section).

• Strategic financing: A Dominican bank has stepped in, creating new acceleration opportunities for future growth.

• Strengthened capital base: The company secured a new €2 million subordinated loan, supporting expansion and stability.

• Market expansion: First steps are being taken into the US market, opening significant long-term potential.

• Team growth: The team continues to expand (with now 15 employees) in line with operations and strategy.

Together, these achievements underline the company’s solid growth path and the strong foundation for continued expansion.

Back to the beginning

Use of funds

The funds raised in this round will bring advanced cancer care to over 2 million people in the Santa Marta region of Colombia, where access is urgently lacking. With your investment, Clínica UHO will install state-of-the-art equipment under Resonandina’s sustainable medical lease model.

With this funding round, Resonandina goes beyond diagnostics to also make life-saving cancer therapy accessible. By adding both a PET/CT scanner for early detection and a Linear Accelerator (Linac) for targeted radiation treatment, Clínica UHO can offer a complete oncology pathway — from accurate diagnosis to effective therapy — under one roof. This marks a major step in delivering comprehensive cancer care to the region.

Depending on the total funding amount, there are three scenarios:

• Scenario 1: Purchase of a PET/CT – a diagnostic imaging device that combines Positron Emission Tomography (PET) and Computed Tomography (CT) to provide highly detailed images, often used to detect and stage cancer, heart disease, and brain disorders.

• Scenario 2: Purchase of a Linac (linear accelerator) – advanced radiotherapy equipment that precisely targets tumors with radiation to destroy cancer cells while sparing healthy tissue.

• Scenario 3 (maximum funding): Purchase of both the PET/CT and the Linac.

In each case, the equipment purchased will serve as collateral for investors, with the collateral structure adapting to the chosen scenario (see table below). Additional the proceeds of the 10 applicable 10 year rental contract.

Actual and planned figures

Get an insight into company name's financial figures, such as turnover and earnings development. Learn more about the growth forecast.

Investment related documents

Log in for more information.

There are currently no updates available.

This section will be regularly updated with new, project-relevant information as the financing progresses. To be informed about new updates in a timely manner, subscribe to our newsletter..